Why Intercept Pharmaceuticals (ICPT) Stock Is Spiking In Pre-Market Trading Today

NEW YORK (TheStreet) -- Intercept Pharmaceuticals  (ICPT) shares are up 45.88% to $346 in pre-market trading on Tuesday after releasing positive data on its fatty liver drug treatment, obeticholic acid (OCA).

The new data shows OCA reduced the signs and symptoms of non-alcoholic steatohepatitis (NASH) compared to placebo. NASH is a disease of the liver that affects 2% to 5% of Americans and has no current treatment.

Intercept plans to start a phase III study of OCA in NASH next year.

Highlights from the analysis by TheStreet Ratings Team follows:

ICPT Chart ICPT data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE

If you liked this article you might like

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Clovis Sell-Off May Be Overdone